
|Articles|June 1, 2001
5-FU cream formulation displays unique profile
Washington - The new 5-fluorouracil (5-FU) 0.5 percent topical cream (Carac) indicated for the treatment of actinic keratoses offers more targeted drug delivery along with the potential for a more favorable safety profile than a previously available formulation containing a 10-fold higher concentration of active ingredient, according to results from comparative studies presented at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















